nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—Dimetacrine—Tamoxifen—pancreatic cancer	0.126	0.39	CrCrCtD
Clomipramine—Clofedanol—Tamoxifen—pancreatic cancer	0.102	0.317	CrCrCtD
Clomipramine—Promazine—Tamoxifen—pancreatic cancer	0.0945	0.293	CrCrCtD
Clomipramine—ALB—Erlotinib—pancreatic cancer	0.0298	0.0821	CbGbCtD
Clomipramine—ALB—Irinotecan—pancreatic cancer	0.0269	0.0742	CbGbCtD
Clomipramine—CYP1A2—Dacarbazine—pancreatic cancer	0.0263	0.0726	CbGbCtD
Clomipramine—ALB—Fluorouracil—pancreatic cancer	0.0258	0.0712	CbGbCtD
Clomipramine—CYP2C19—Tamoxifen—pancreatic cancer	0.0227	0.0626	CbGbCtD
Clomipramine—CYP1A2—Tamoxifen—pancreatic cancer	0.0209	0.0578	CbGbCtD
Clomipramine—HRH2—gastric juice—pancreatic cancer	0.0187	0.483	CbGeAlD
Clomipramine—ABCB1—Tamoxifen—pancreatic cancer	0.0183	0.0505	CbGbCtD
Clomipramine—CYP1A2—Erlotinib—pancreatic cancer	0.0178	0.0491	CbGbCtD
Clomipramine—CYP2D6—Tamoxifen—pancreatic cancer	0.0173	0.0476	CbGbCtD
Clomipramine—ABCB1—Gemcitabine—pancreatic cancer	0.0158	0.0435	CbGbCtD
Clomipramine—ABCB1—Erlotinib—pancreatic cancer	0.0156	0.043	CbGbCtD
Clomipramine—CYP1A2—Fluorouracil—pancreatic cancer	0.0154	0.0426	CbGbCtD
Clomipramine—CYP2D6—Erlotinib—pancreatic cancer	0.0147	0.0405	CbGbCtD
Clomipramine—ABCB1—Irinotecan—pancreatic cancer	0.0141	0.0388	CbGbCtD
Clomipramine—CYP3A4—Tamoxifen—pancreatic cancer	0.011	0.0303	CbGbCtD
Clomipramine—ABCB1—Docetaxel—pancreatic cancer	0.0103	0.0284	CbGbCtD
Clomipramine—ABCB1—Sunitinib—pancreatic cancer	0.0103	0.0283	CbGbCtD
Clomipramine—CYP3A4—Erlotinib—pancreatic cancer	0.00933	0.0257	CbGbCtD
Clomipramine—CYP3A4—Irinotecan—pancreatic cancer	0.00842	0.0232	CbGbCtD
Clomipramine—ABCB1—Doxorubicin—pancreatic cancer	0.00768	0.0212	CbGbCtD
Clomipramine—CYP2D6—Doxorubicin—pancreatic cancer	0.00724	0.02	CbGbCtD
Clomipramine—HTR2A—enteric nervous system—pancreatic cancer	0.00631	0.163	CbGeAlD
Clomipramine—CYP3A4—Docetaxel—pancreatic cancer	0.00617	0.017	CbGbCtD
Clomipramine—CYP3A4—Sunitinib—pancreatic cancer	0.00614	0.017	CbGbCtD
Clomipramine—CYP3A4—Doxorubicin—pancreatic cancer	0.0046	0.0127	CbGbCtD
Clomipramine—GSTP1—gall bladder—pancreatic cancer	0.00209	0.0539	CbGeAlD
Clomipramine—ALB—gall bladder—pancreatic cancer	0.00179	0.0462	CbGeAlD
Clomipramine—GSTP1—islet of Langerhans—pancreatic cancer	0.00137	0.0353	CbGeAlD
Clomipramine—HRH2—digestive system—pancreatic cancer	0.00114	0.0295	CbGeAlD
Clomipramine—GSTP1—pancreas—pancreatic cancer	0.000963	0.0248	CbGeAlD
Clomipramine—GSTP1—digestive system—pancreatic cancer	0.000823	0.0212	CbGeAlD
Clomipramine—ADRA2A—islet of Langerhans—pancreatic cancer	0.00071	0.0183	CbGeAlD
Clomipramine—SLC6A4—digestive system—pancreatic cancer	0.000685	0.0177	CbGeAlD
Clomipramine—HTR2B—digestive system—pancreatic cancer	0.000678	0.0175	CbGeAlD
Clomipramine—CYP2C19—digestive system—pancreatic cancer	0.000567	0.0146	CbGeAlD
Clomipramine—ADRA2A—pancreas—pancreatic cancer	0.000499	0.0129	CbGeAlD
Clomipramine—CYP1A2—digestive system—pancreatic cancer	0.000463	0.012	CbGeAlD
Clomipramine—ABCB1—islet of Langerhans—pancreatic cancer	0.000395	0.0102	CbGeAlD
Clomipramine—HTR2A—digestive system—pancreatic cancer	0.000362	0.00934	CbGeAlD
Clomipramine—CYP3A4—digestive system—pancreatic cancer	0.000335	0.00865	CbGeAlD
Clomipramine—CYP2D6—digestive system—pancreatic cancer	0.00033	0.00851	CbGeAlD
Clomipramine—ABCB1—pancreas—pancreatic cancer	0.000278	0.00717	CbGeAlD
Clomipramine—ABCB1—digestive system—pancreatic cancer	0.000237	0.00612	CbGeAlD
Clomipramine—Dry mouth—Docetaxel—pancreatic cancer	7.94e-05	0.000405	CcSEcCtD
Clomipramine—Sweating—Epirubicin—pancreatic cancer	7.89e-05	0.000402	CcSEcCtD
Clomipramine—Pollakiuria—Doxorubicin—pancreatic cancer	7.89e-05	0.000402	CcSEcCtD
Clomipramine—Asthenia—Gemcitabine—pancreatic cancer	7.87e-05	0.000401	CcSEcCtD
Clomipramine—Haematuria—Epirubicin—pancreatic cancer	7.85e-05	0.0004	CcSEcCtD
Clomipramine—Confusional state—Docetaxel—pancreatic cancer	7.85e-05	0.0004	CcSEcCtD
Clomipramine—Photosensitivity reaction—Doxorubicin—pancreatic cancer	7.8e-05	0.000398	CcSEcCtD
Clomipramine—Hepatobiliary disease—Epirubicin—pancreatic cancer	7.79e-05	0.000397	CcSEcCtD
Clomipramine—Anaphylactic shock—Docetaxel—pancreatic cancer	7.79e-05	0.000397	CcSEcCtD
Clomipramine—Oedema—Docetaxel—pancreatic cancer	7.79e-05	0.000397	CcSEcCtD
Clomipramine—Weight increased—Doxorubicin—pancreatic cancer	7.78e-05	0.000396	CcSEcCtD
Clomipramine—Epistaxis—Epirubicin—pancreatic cancer	7.77e-05	0.000396	CcSEcCtD
Clomipramine—Pruritus—Gemcitabine—pancreatic cancer	7.76e-05	0.000396	CcSEcCtD
Clomipramine—Weight decreased—Doxorubicin—pancreatic cancer	7.73e-05	0.000394	CcSEcCtD
Clomipramine—Sinusitis—Epirubicin—pancreatic cancer	7.73e-05	0.000394	CcSEcCtD
Clomipramine—Hyperglycaemia—Doxorubicin—pancreatic cancer	7.71e-05	0.000393	CcSEcCtD
Clomipramine—Diarrhoea—Irinotecan—pancreatic cancer	7.71e-05	0.000393	CcSEcCtD
Clomipramine—Agranulocytosis—Epirubicin—pancreatic cancer	7.68e-05	0.000392	CcSEcCtD
Clomipramine—Pneumonia—Doxorubicin—pancreatic cancer	7.66e-05	0.000391	CcSEcCtD
Clomipramine—Shock—Docetaxel—pancreatic cancer	7.66e-05	0.00039	CcSEcCtD
Clomipramine—Nervous system disorder—Docetaxel—pancreatic cancer	7.64e-05	0.000389	CcSEcCtD
Clomipramine—Pruritus—Fluorouracil—pancreatic cancer	7.63e-05	0.000389	CcSEcCtD
Clomipramine—Thrombocytopenia—Docetaxel—pancreatic cancer	7.62e-05	0.000389	CcSEcCtD
Clomipramine—Drowsiness—Doxorubicin—pancreatic cancer	7.62e-05	0.000388	CcSEcCtD
Clomipramine—Tachycardia—Docetaxel—pancreatic cancer	7.6e-05	0.000387	CcSEcCtD
Clomipramine—Skin disorder—Docetaxel—pancreatic cancer	7.56e-05	0.000385	CcSEcCtD
Clomipramine—Bradycardia—Epirubicin—pancreatic cancer	7.53e-05	0.000384	CcSEcCtD
Clomipramine—Diarrhoea—Gemcitabine—pancreatic cancer	7.51e-05	0.000383	CcSEcCtD
Clomipramine—Neuropathy peripheral—Doxorubicin—pancreatic cancer	7.47e-05	0.000381	CcSEcCtD
Clomipramine—Dizziness—Irinotecan—pancreatic cancer	7.45e-05	0.00038	CcSEcCtD
Clomipramine—Jaundice—Doxorubicin—pancreatic cancer	7.43e-05	0.000379	CcSEcCtD
Clomipramine—Anorexia—Docetaxel—pancreatic cancer	7.42e-05	0.000378	CcSEcCtD
Clomipramine—Rhinitis—Epirubicin—pancreatic cancer	7.41e-05	0.000378	CcSEcCtD
Clomipramine—Conjunctivitis—Doxorubicin—pancreatic cancer	7.41e-05	0.000377	CcSEcCtD
Clomipramine—Urinary tract infection—Doxorubicin—pancreatic cancer	7.41e-05	0.000377	CcSEcCtD
Clomipramine—Hepatitis—Epirubicin—pancreatic cancer	7.39e-05	0.000377	CcSEcCtD
Clomipramine—Diarrhoea—Fluorouracil—pancreatic cancer	7.38e-05	0.000376	CcSEcCtD
Clomipramine—Hypoaesthesia—Epirubicin—pancreatic cancer	7.36e-05	0.000375	CcSEcCtD
Clomipramine—Pharyngitis—Epirubicin—pancreatic cancer	7.34e-05	0.000374	CcSEcCtD
Clomipramine—Sweating—Doxorubicin—pancreatic cancer	7.3e-05	0.000372	CcSEcCtD
Clomipramine—Urinary tract disorder—Epirubicin—pancreatic cancer	7.3e-05	0.000372	CcSEcCtD
Clomipramine—Hypotension—Docetaxel—pancreatic cancer	7.28e-05	0.000371	CcSEcCtD
Clomipramine—Haematuria—Doxorubicin—pancreatic cancer	7.26e-05	0.00037	CcSEcCtD
Clomipramine—Connective tissue disorder—Epirubicin—pancreatic cancer	7.26e-05	0.00037	CcSEcCtD
Clomipramine—Urethral disorder—Epirubicin—pancreatic cancer	7.25e-05	0.000369	CcSEcCtD
Clomipramine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	7.21e-05	0.000367	CcSEcCtD
Clomipramine—Epistaxis—Doxorubicin—pancreatic cancer	7.19e-05	0.000366	CcSEcCtD
Clomipramine—Vomiting—Irinotecan—pancreatic cancer	7.16e-05	0.000365	CcSEcCtD
Clomipramine—Sinusitis—Doxorubicin—pancreatic cancer	7.15e-05	0.000364	CcSEcCtD
Clomipramine—Dizziness—Fluorouracil—pancreatic cancer	7.13e-05	0.000364	CcSEcCtD
Clomipramine—Visual impairment—Epirubicin—pancreatic cancer	7.12e-05	0.000363	CcSEcCtD
Clomipramine—Agranulocytosis—Doxorubicin—pancreatic cancer	7.11e-05	0.000362	CcSEcCtD
Clomipramine—Rash—Irinotecan—pancreatic cancer	7.1e-05	0.000362	CcSEcCtD
Clomipramine—Dermatitis—Irinotecan—pancreatic cancer	7.1e-05	0.000362	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.09e-05	0.000362	CcSEcCtD
Clomipramine—Headache—Irinotecan—pancreatic cancer	7.06e-05	0.00036	CcSEcCtD
Clomipramine—Insomnia—Docetaxel—pancreatic cancer	7.04e-05	0.000359	CcSEcCtD
Clomipramine—Paraesthesia—Docetaxel—pancreatic cancer	6.99e-05	0.000356	CcSEcCtD
Clomipramine—Vomiting—Gemcitabine—pancreatic cancer	6.98e-05	0.000356	CcSEcCtD
Clomipramine—Bradycardia—Doxorubicin—pancreatic cancer	6.96e-05	0.000355	CcSEcCtD
Clomipramine—Dyspnoea—Docetaxel—pancreatic cancer	6.94e-05	0.000354	CcSEcCtD
Clomipramine—Somnolence—Docetaxel—pancreatic cancer	6.92e-05	0.000353	CcSEcCtD
Clomipramine—Rash—Gemcitabine—pancreatic cancer	6.92e-05	0.000353	CcSEcCtD
Clomipramine—Dermatitis—Gemcitabine—pancreatic cancer	6.91e-05	0.000352	CcSEcCtD
Clomipramine—Eye disorder—Epirubicin—pancreatic cancer	6.91e-05	0.000352	CcSEcCtD
Clomipramine—Tinnitus—Epirubicin—pancreatic cancer	6.89e-05	0.000351	CcSEcCtD
Clomipramine—Headache—Gemcitabine—pancreatic cancer	6.87e-05	0.00035	CcSEcCtD
Clomipramine—Cardiac disorder—Epirubicin—pancreatic cancer	6.86e-05	0.00035	CcSEcCtD
Clomipramine—Flushing—Epirubicin—pancreatic cancer	6.86e-05	0.00035	CcSEcCtD
Clomipramine—Vomiting—Fluorouracil—pancreatic cancer	6.86e-05	0.00035	CcSEcCtD
Clomipramine—Rhinitis—Doxorubicin—pancreatic cancer	6.86e-05	0.000349	CcSEcCtD
Clomipramine—Dyspepsia—Docetaxel—pancreatic cancer	6.85e-05	0.000349	CcSEcCtD
Clomipramine—Hepatitis—Doxorubicin—pancreatic cancer	6.84e-05	0.000349	CcSEcCtD
Clomipramine—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.81e-05	0.000347	CcSEcCtD
Clomipramine—Rash—Fluorouracil—pancreatic cancer	6.8e-05	0.000347	CcSEcCtD
Clomipramine—Dermatitis—Fluorouracil—pancreatic cancer	6.8e-05	0.000346	CcSEcCtD
Clomipramine—Pharyngitis—Doxorubicin—pancreatic cancer	6.79e-05	0.000346	CcSEcCtD
Clomipramine—Decreased appetite—Docetaxel—pancreatic cancer	6.77e-05	0.000345	CcSEcCtD
Clomipramine—Headache—Fluorouracil—pancreatic cancer	6.76e-05	0.000344	CcSEcCtD
Clomipramine—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.75e-05	0.000344	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.72e-05	0.000343	CcSEcCtD
Clomipramine—Connective tissue disorder—Doxorubicin—pancreatic cancer	6.72e-05	0.000343	CcSEcCtD
Clomipramine—Fatigue—Docetaxel—pancreatic cancer	6.71e-05	0.000342	CcSEcCtD
Clomipramine—Angiopathy—Epirubicin—pancreatic cancer	6.71e-05	0.000342	CcSEcCtD
Clomipramine—Urethral disorder—Doxorubicin—pancreatic cancer	6.7e-05	0.000342	CcSEcCtD
Clomipramine—Nausea—Irinotecan—pancreatic cancer	6.69e-05	0.000341	CcSEcCtD
Clomipramine—Immune system disorder—Epirubicin—pancreatic cancer	6.68e-05	0.00034	CcSEcCtD
Clomipramine—Mediastinal disorder—Epirubicin—pancreatic cancer	6.66e-05	0.00034	CcSEcCtD
Clomipramine—Constipation—Docetaxel—pancreatic cancer	6.66e-05	0.000339	CcSEcCtD
Clomipramine—Pain—Docetaxel—pancreatic cancer	6.66e-05	0.000339	CcSEcCtD
Clomipramine—Chills—Epirubicin—pancreatic cancer	6.63e-05	0.000338	CcSEcCtD
Clomipramine—Arrhythmia—Epirubicin—pancreatic cancer	6.6e-05	0.000337	CcSEcCtD
Clomipramine—Visual impairment—Doxorubicin—pancreatic cancer	6.59e-05	0.000336	CcSEcCtD
Clomipramine—Alopecia—Epirubicin—pancreatic cancer	6.53e-05	0.000333	CcSEcCtD
Clomipramine—Nausea—Gemcitabine—pancreatic cancer	6.52e-05	0.000332	CcSEcCtD
Clomipramine—Mental disorder—Epirubicin—pancreatic cancer	6.48e-05	0.00033	CcSEcCtD
Clomipramine—Malnutrition—Epirubicin—pancreatic cancer	6.44e-05	0.000328	CcSEcCtD
Clomipramine—Feeling abnormal—Docetaxel—pancreatic cancer	6.42e-05	0.000327	CcSEcCtD
Clomipramine—Nausea—Fluorouracil—pancreatic cancer	6.41e-05	0.000327	CcSEcCtD
Clomipramine—Eye disorder—Doxorubicin—pancreatic cancer	6.39e-05	0.000326	CcSEcCtD
Clomipramine—Tinnitus—Doxorubicin—pancreatic cancer	6.38e-05	0.000325	CcSEcCtD
Clomipramine—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.37e-05	0.000325	CcSEcCtD
Clomipramine—Flushing—Doxorubicin—pancreatic cancer	6.35e-05	0.000324	CcSEcCtD
Clomipramine—Cardiac disorder—Doxorubicin—pancreatic cancer	6.35e-05	0.000324	CcSEcCtD
Clomipramine—Flatulence—Epirubicin—pancreatic cancer	6.34e-05	0.000323	CcSEcCtD
Clomipramine—Tension—Epirubicin—pancreatic cancer	6.31e-05	0.000322	CcSEcCtD
Clomipramine—Dysgeusia—Epirubicin—pancreatic cancer	6.3e-05	0.000321	CcSEcCtD
Clomipramine—Nervousness—Epirubicin—pancreatic cancer	6.25e-05	0.000319	CcSEcCtD
Clomipramine—Back pain—Epirubicin—pancreatic cancer	6.22e-05	0.000317	CcSEcCtD
Clomipramine—Angiopathy—Doxorubicin—pancreatic cancer	6.21e-05	0.000316	CcSEcCtD
Clomipramine—Muscle spasms—Epirubicin—pancreatic cancer	6.19e-05	0.000315	CcSEcCtD
Clomipramine—Immune system disorder—Doxorubicin—pancreatic cancer	6.18e-05	0.000315	CcSEcCtD
Clomipramine—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.16e-05	0.000314	CcSEcCtD
Clomipramine—Abdominal pain—Docetaxel—pancreatic cancer	6.16e-05	0.000314	CcSEcCtD
Clomipramine—Body temperature increased—Docetaxel—pancreatic cancer	6.16e-05	0.000314	CcSEcCtD
Clomipramine—Chills—Doxorubicin—pancreatic cancer	6.14e-05	0.000313	CcSEcCtD
Clomipramine—Arrhythmia—Doxorubicin—pancreatic cancer	6.11e-05	0.000311	CcSEcCtD
Clomipramine—Vision blurred—Epirubicin—pancreatic cancer	6.06e-05	0.000309	CcSEcCtD
Clomipramine—Alopecia—Doxorubicin—pancreatic cancer	6.04e-05	0.000308	CcSEcCtD
Clomipramine—Mental disorder—Doxorubicin—pancreatic cancer	5.99e-05	0.000305	CcSEcCtD
Clomipramine—Ill-defined disorder—Epirubicin—pancreatic cancer	5.97e-05	0.000304	CcSEcCtD
Clomipramine—Malnutrition—Doxorubicin—pancreatic cancer	5.95e-05	0.000303	CcSEcCtD
Clomipramine—Anaemia—Epirubicin—pancreatic cancer	5.95e-05	0.000303	CcSEcCtD
Clomipramine—Agitation—Epirubicin—pancreatic cancer	5.91e-05	0.000301	CcSEcCtD
Clomipramine—Flatulence—Doxorubicin—pancreatic cancer	5.87e-05	0.000299	CcSEcCtD
Clomipramine—Tension—Doxorubicin—pancreatic cancer	5.84e-05	0.000298	CcSEcCtD
Clomipramine—Dysgeusia—Doxorubicin—pancreatic cancer	5.83e-05	0.000297	CcSEcCtD
Clomipramine—Malaise—Epirubicin—pancreatic cancer	5.8e-05	0.000296	CcSEcCtD
Clomipramine—Nervousness—Doxorubicin—pancreatic cancer	5.78e-05	0.000295	CcSEcCtD
Clomipramine—Vertigo—Epirubicin—pancreatic cancer	5.78e-05	0.000295	CcSEcCtD
Clomipramine—Syncope—Epirubicin—pancreatic cancer	5.77e-05	0.000294	CcSEcCtD
Clomipramine—Leukopenia—Epirubicin—pancreatic cancer	5.76e-05	0.000294	CcSEcCtD
Clomipramine—Back pain—Doxorubicin—pancreatic cancer	5.76e-05	0.000294	CcSEcCtD
Clomipramine—Hypersensitivity—Docetaxel—pancreatic cancer	5.74e-05	0.000292	CcSEcCtD
Clomipramine—Muscle spasms—Doxorubicin—pancreatic cancer	5.72e-05	0.000292	CcSEcCtD
Clomipramine—Palpitations—Epirubicin—pancreatic cancer	5.69e-05	0.00029	CcSEcCtD
Clomipramine—Loss of consciousness—Epirubicin—pancreatic cancer	5.66e-05	0.000288	CcSEcCtD
Clomipramine—Cough—Epirubicin—pancreatic cancer	5.62e-05	0.000286	CcSEcCtD
Clomipramine—Vision blurred—Doxorubicin—pancreatic cancer	5.61e-05	0.000286	CcSEcCtD
Clomipramine—Asthenia—Docetaxel—pancreatic cancer	5.59e-05	0.000285	CcSEcCtD
Clomipramine—Convulsion—Epirubicin—pancreatic cancer	5.58e-05	0.000284	CcSEcCtD
Clomipramine—Hypertension—Epirubicin—pancreatic cancer	5.56e-05	0.000283	CcSEcCtD
Clomipramine—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.52e-05	0.000282	CcSEcCtD
Clomipramine—Pruritus—Docetaxel—pancreatic cancer	5.51e-05	0.000281	CcSEcCtD
Clomipramine—Anaemia—Doxorubicin—pancreatic cancer	5.5e-05	0.00028	CcSEcCtD
Clomipramine—Arthralgia—Epirubicin—pancreatic cancer	5.48e-05	0.000279	CcSEcCtD
Clomipramine—Chest pain—Epirubicin—pancreatic cancer	5.48e-05	0.000279	CcSEcCtD
Clomipramine—Myalgia—Epirubicin—pancreatic cancer	5.48e-05	0.000279	CcSEcCtD
Clomipramine—Agitation—Doxorubicin—pancreatic cancer	5.47e-05	0.000279	CcSEcCtD
Clomipramine—Anxiety—Epirubicin—pancreatic cancer	5.46e-05	0.000278	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.44e-05	0.000277	CcSEcCtD
Clomipramine—Discomfort—Epirubicin—pancreatic cancer	5.41e-05	0.000276	CcSEcCtD
Clomipramine—Malaise—Doxorubicin—pancreatic cancer	5.37e-05	0.000274	CcSEcCtD
Clomipramine—Dry mouth—Epirubicin—pancreatic cancer	5.36e-05	0.000273	CcSEcCtD
Clomipramine—Vertigo—Doxorubicin—pancreatic cancer	5.35e-05	0.000273	CcSEcCtD
Clomipramine—Syncope—Doxorubicin—pancreatic cancer	5.34e-05	0.000272	CcSEcCtD
Clomipramine—Leukopenia—Doxorubicin—pancreatic cancer	5.33e-05	0.000272	CcSEcCtD
Clomipramine—Diarrhoea—Docetaxel—pancreatic cancer	5.33e-05	0.000272	CcSEcCtD
Clomipramine—Confusional state—Epirubicin—pancreatic cancer	5.3e-05	0.00027	CcSEcCtD
Clomipramine—Palpitations—Doxorubicin—pancreatic cancer	5.26e-05	0.000268	CcSEcCtD
Clomipramine—Oedema—Epirubicin—pancreatic cancer	5.25e-05	0.000268	CcSEcCtD
Clomipramine—Anaphylactic shock—Epirubicin—pancreatic cancer	5.25e-05	0.000268	CcSEcCtD
Clomipramine—Loss of consciousness—Doxorubicin—pancreatic cancer	5.23e-05	0.000267	CcSEcCtD
Clomipramine—Cough—Doxorubicin—pancreatic cancer	5.2e-05	0.000265	CcSEcCtD
Clomipramine—Shock—Epirubicin—pancreatic cancer	5.17e-05	0.000263	CcSEcCtD
Clomipramine—Convulsion—Doxorubicin—pancreatic cancer	5.16e-05	0.000263	CcSEcCtD
Clomipramine—Nervous system disorder—Epirubicin—pancreatic cancer	5.15e-05	0.000262	CcSEcCtD
Clomipramine—Dizziness—Docetaxel—pancreatic cancer	5.15e-05	0.000262	CcSEcCtD
Clomipramine—Thrombocytopenia—Epirubicin—pancreatic cancer	5.14e-05	0.000262	CcSEcCtD
Clomipramine—Hypertension—Doxorubicin—pancreatic cancer	5.14e-05	0.000262	CcSEcCtD
Clomipramine—Tachycardia—Epirubicin—pancreatic cancer	5.13e-05	0.000261	CcSEcCtD
Clomipramine—Skin disorder—Epirubicin—pancreatic cancer	5.1e-05	0.00026	CcSEcCtD
Clomipramine—Hyperhidrosis—Epirubicin—pancreatic cancer	5.08e-05	0.000259	CcSEcCtD
Clomipramine—Arthralgia—Doxorubicin—pancreatic cancer	5.07e-05	0.000258	CcSEcCtD
Clomipramine—Chest pain—Doxorubicin—pancreatic cancer	5.07e-05	0.000258	CcSEcCtD
Clomipramine—Myalgia—Doxorubicin—pancreatic cancer	5.07e-05	0.000258	CcSEcCtD
Clomipramine—Anxiety—Doxorubicin—pancreatic cancer	5.05e-05	0.000257	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.03e-05	0.000257	CcSEcCtD
Clomipramine—Discomfort—Doxorubicin—pancreatic cancer	5.01e-05	0.000255	CcSEcCtD
Clomipramine—Anorexia—Epirubicin—pancreatic cancer	5.01e-05	0.000255	CcSEcCtD
Clomipramine—Dry mouth—Doxorubicin—pancreatic cancer	4.96e-05	0.000253	CcSEcCtD
Clomipramine—Vomiting—Docetaxel—pancreatic cancer	4.95e-05	0.000252	CcSEcCtD
Clomipramine—Rash—Docetaxel—pancreatic cancer	4.91e-05	0.00025	CcSEcCtD
Clomipramine—Hypotension—Epirubicin—pancreatic cancer	4.91e-05	0.00025	CcSEcCtD
Clomipramine—Dermatitis—Docetaxel—pancreatic cancer	4.9e-05	0.00025	CcSEcCtD
Clomipramine—Confusional state—Doxorubicin—pancreatic cancer	4.9e-05	0.00025	CcSEcCtD
Clomipramine—Headache—Docetaxel—pancreatic cancer	4.88e-05	0.000249	CcSEcCtD
Clomipramine—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.86e-05	0.000248	CcSEcCtD
Clomipramine—Oedema—Doxorubicin—pancreatic cancer	4.86e-05	0.000248	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.78e-05	0.000244	CcSEcCtD
Clomipramine—Shock—Doxorubicin—pancreatic cancer	4.78e-05	0.000244	CcSEcCtD
Clomipramine—Nervous system disorder—Doxorubicin—pancreatic cancer	4.77e-05	0.000243	CcSEcCtD
Clomipramine—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.76e-05	0.000242	CcSEcCtD
Clomipramine—Insomnia—Epirubicin—pancreatic cancer	4.75e-05	0.000242	CcSEcCtD
Clomipramine—Tachycardia—Doxorubicin—pancreatic cancer	4.74e-05	0.000242	CcSEcCtD
Clomipramine—Skin disorder—Doxorubicin—pancreatic cancer	4.72e-05	0.000241	CcSEcCtD
Clomipramine—Paraesthesia—Epirubicin—pancreatic cancer	4.72e-05	0.00024	CcSEcCtD
Clomipramine—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.7e-05	0.000239	CcSEcCtD
Clomipramine—Dyspnoea—Epirubicin—pancreatic cancer	4.68e-05	0.000239	CcSEcCtD
Clomipramine—Somnolence—Epirubicin—pancreatic cancer	4.67e-05	0.000238	CcSEcCtD
Clomipramine—Anorexia—Doxorubicin—pancreatic cancer	4.63e-05	0.000236	CcSEcCtD
Clomipramine—Nausea—Docetaxel—pancreatic cancer	4.62e-05	0.000236	CcSEcCtD
Clomipramine—Dyspepsia—Epirubicin—pancreatic cancer	4.62e-05	0.000236	CcSEcCtD
Clomipramine—Decreased appetite—Epirubicin—pancreatic cancer	4.57e-05	0.000233	CcSEcCtD
Clomipramine—Hypotension—Doxorubicin—pancreatic cancer	4.54e-05	0.000231	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.53e-05	0.000231	CcSEcCtD
Clomipramine—Fatigue—Epirubicin—pancreatic cancer	4.53e-05	0.000231	CcSEcCtD
Clomipramine—Constipation—Epirubicin—pancreatic cancer	4.49e-05	0.000229	CcSEcCtD
Clomipramine—Pain—Epirubicin—pancreatic cancer	4.49e-05	0.000229	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.43e-05	0.000226	CcSEcCtD
Clomipramine—Insomnia—Doxorubicin—pancreatic cancer	4.4e-05	0.000224	CcSEcCtD
Clomipramine—Paraesthesia—Doxorubicin—pancreatic cancer	4.36e-05	0.000222	CcSEcCtD
Clomipramine—Dyspnoea—Doxorubicin—pancreatic cancer	4.33e-05	0.000221	CcSEcCtD
Clomipramine—Feeling abnormal—Epirubicin—pancreatic cancer	4.33e-05	0.000221	CcSEcCtD
Clomipramine—Somnolence—Doxorubicin—pancreatic cancer	4.32e-05	0.00022	CcSEcCtD
Clomipramine—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.29e-05	0.000219	CcSEcCtD
Clomipramine—Dyspepsia—Doxorubicin—pancreatic cancer	4.28e-05	0.000218	CcSEcCtD
Clomipramine—Decreased appetite—Doxorubicin—pancreatic cancer	4.22e-05	0.000215	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.2e-05	0.000214	CcSEcCtD
Clomipramine—Fatigue—Doxorubicin—pancreatic cancer	4.19e-05	0.000214	CcSEcCtD
Clomipramine—Urticaria—Epirubicin—pancreatic cancer	4.17e-05	0.000213	CcSEcCtD
Clomipramine—Constipation—Doxorubicin—pancreatic cancer	4.16e-05	0.000212	CcSEcCtD
Clomipramine—Pain—Doxorubicin—pancreatic cancer	4.16e-05	0.000212	CcSEcCtD
Clomipramine—Abdominal pain—Epirubicin—pancreatic cancer	4.15e-05	0.000212	CcSEcCtD
Clomipramine—Body temperature increased—Epirubicin—pancreatic cancer	4.15e-05	0.000212	CcSEcCtD
Clomipramine—Feeling abnormal—Doxorubicin—pancreatic cancer	4e-05	0.000204	CcSEcCtD
Clomipramine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.97e-05	0.000203	CcSEcCtD
Clomipramine—Hypersensitivity—Epirubicin—pancreatic cancer	3.87e-05	0.000197	CcSEcCtD
Clomipramine—Urticaria—Doxorubicin—pancreatic cancer	3.86e-05	0.000197	CcSEcCtD
Clomipramine—Abdominal pain—Doxorubicin—pancreatic cancer	3.84e-05	0.000196	CcSEcCtD
Clomipramine—Body temperature increased—Doxorubicin—pancreatic cancer	3.84e-05	0.000196	CcSEcCtD
Clomipramine—Asthenia—Epirubicin—pancreatic cancer	3.77e-05	0.000192	CcSEcCtD
Clomipramine—Pruritus—Epirubicin—pancreatic cancer	3.72e-05	0.000189	CcSEcCtD
Clomipramine—Diarrhoea—Epirubicin—pancreatic cancer	3.59e-05	0.000183	CcSEcCtD
Clomipramine—Hypersensitivity—Doxorubicin—pancreatic cancer	3.58e-05	0.000182	CcSEcCtD
Clomipramine—Asthenia—Doxorubicin—pancreatic cancer	3.49e-05	0.000178	CcSEcCtD
Clomipramine—Dizziness—Epirubicin—pancreatic cancer	3.47e-05	0.000177	CcSEcCtD
Clomipramine—Pruritus—Doxorubicin—pancreatic cancer	3.44e-05	0.000175	CcSEcCtD
Clomipramine—Vomiting—Epirubicin—pancreatic cancer	3.34e-05	0.00017	CcSEcCtD
Clomipramine—Diarrhoea—Doxorubicin—pancreatic cancer	3.32e-05	0.000169	CcSEcCtD
Clomipramine—Rash—Epirubicin—pancreatic cancer	3.31e-05	0.000169	CcSEcCtD
Clomipramine—Dermatitis—Epirubicin—pancreatic cancer	3.31e-05	0.000169	CcSEcCtD
Clomipramine—Headache—Epirubicin—pancreatic cancer	3.29e-05	0.000168	CcSEcCtD
Clomipramine—Dizziness—Doxorubicin—pancreatic cancer	3.21e-05	0.000164	CcSEcCtD
Clomipramine—Nausea—Epirubicin—pancreatic cancer	3.12e-05	0.000159	CcSEcCtD
Clomipramine—Vomiting—Doxorubicin—pancreatic cancer	3.09e-05	0.000157	CcSEcCtD
Clomipramine—Rash—Doxorubicin—pancreatic cancer	3.06e-05	0.000156	CcSEcCtD
Clomipramine—Dermatitis—Doxorubicin—pancreatic cancer	3.06e-05	0.000156	CcSEcCtD
Clomipramine—Headache—Doxorubicin—pancreatic cancer	3.04e-05	0.000155	CcSEcCtD
Clomipramine—Nausea—Doxorubicin—pancreatic cancer	2.89e-05	0.000147	CcSEcCtD
Clomipramine—HTR2C—Signaling Pathways—NOTCH1—pancreatic cancer	7.39e-06	9.27e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—TYMS—pancreatic cancer	7.34e-06	9.21e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TGFB1—pancreatic cancer	7.29e-06	9.15e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	7.28e-06	9.13e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CG—pancreatic cancer	7.23e-06	9.06e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—NRAS—pancreatic cancer	7.23e-06	9.06e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CXCL8—pancreatic cancer	7.23e-06	9.06e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.19e-06	9.02e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—HRAS—pancreatic cancer	7.18e-06	9e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGF—pancreatic cancer	7.14e-06	8.96e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	7.12e-06	8.93e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	7.12e-06	8.93e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	7.11e-06	8.91e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—PIK3CA—pancreatic cancer	7.08e-06	8.88e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.07e-06	8.87e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—STK11—pancreatic cancer	7.05e-06	8.84e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MYC—pancreatic cancer	7.04e-06	8.83e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TGFB1—pancreatic cancer	7.02e-06	8.81e-05	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—AKT1—pancreatic cancer	6.98e-06	8.75e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—DPYD—pancreatic cancer	6.95e-06	8.72e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—APOE—pancreatic cancer	6.95e-06	8.72e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CASP3—pancreatic cancer	6.92e-06	8.67e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EGFR—pancreatic cancer	6.89e-06	8.64e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PIK3CB—pancreatic cancer	6.86e-06	8.61e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	6.83e-06	8.56e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—KDR—pancreatic cancer	6.81e-06	8.54e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	6.78e-06	8.5e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—KRAS—pancreatic cancer	6.76e-06	8.47e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCND1—pancreatic cancer	6.73e-06	8.44e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CTNNB1—pancreatic cancer	6.67e-06	8.36e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CD44—pancreatic cancer	6.62e-06	8.31e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.6e-06	8.28e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCL8—pancreatic cancer	6.6e-06	8.27e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—TYMS—pancreatic cancer	6.59e-06	8.27e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PPARG—pancreatic cancer	6.59e-06	8.26e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EGFR—pancreatic cancer	6.58e-06	8.26e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—HRAS—pancreatic cancer	6.55e-06	8.22e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—pancreatic cancer	6.54e-06	8.2e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—KRAS—pancreatic cancer	6.5e-06	8.16e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PTEN—pancreatic cancer	6.5e-06	8.15e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	6.48e-06	8.13e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	6.48e-06	8.13e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	6.48e-06	8.13e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	6.46e-06	8.11e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TYMS—pancreatic cancer	6.43e-06	8.07e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	6.43e-06	8.06e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	6.43e-06	8.06e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	6.42e-06	8.05e-05	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	6.37e-06	7.99e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	6.35e-06	7.97e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GCG—pancreatic cancer	6.35e-06	7.96e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AKT1—pancreatic cancer	6.34e-06	7.95e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	6.33e-06	7.93e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	6.31e-06	7.92e-05	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.29e-06	7.89e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	6.28e-06	7.87e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	6.27e-06	7.87e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	6.22e-06	7.8e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—PIK3CA—pancreatic cancer	6.21e-06	7.79e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGF—pancreatic cancer	6.2e-06	7.78e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	6.2e-06	7.77e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	6.14e-06	7.71e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	6.08e-06	7.63e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TYMS—pancreatic cancer	6.06e-06	7.6e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—SRC—pancreatic cancer	6.03e-06	7.56e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—pancreatic cancer	6.01e-06	7.53e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	6e-06	7.53e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PIK3CA—pancreatic cancer	5.98e-06	7.5e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APOE—pancreatic cancer	5.97e-06	7.49e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—STK11—pancreatic cancer	5.97e-06	7.49e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	5.97e-06	7.48e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	5.93e-06	7.44e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	5.89e-06	7.39e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—VEGFA—pancreatic cancer	5.87e-06	7.36e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	5.84e-06	7.32e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—STAT3—pancreatic cancer	5.81e-06	7.29e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NRAS—pancreatic cancer	5.8e-06	7.27e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	5.79e-06	7.26e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—pancreatic cancer	5.78e-06	7.25e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—HRAS—pancreatic cancer	5.74e-06	7.2e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	5.72e-06	7.17e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	5.71e-06	7.17e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	5.71e-06	7.16e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	5.71e-06	7.16e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.65e-06	7.09e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	5.64e-06	7.08e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.6e-06	7.03e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	5.54e-06	6.94e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—HRAS—pancreatic cancer	5.53e-06	6.93e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	5.52e-06	6.92e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—SRC—pancreatic cancer	5.5e-06	6.9e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.46e-06	6.85e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	5.4e-06	6.77e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MYC—pancreatic cancer	5.4e-06	6.77e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CG—pancreatic cancer	5.39e-06	6.76e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TGFB1—pancreatic cancer	5.39e-06	6.76e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APOE—pancreatic cancer	5.36e-06	6.72e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	5.36e-06	6.72e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	5.32e-06	6.67e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	5.3e-06	6.65e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	5.29e-06	6.64e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	5.29e-06	6.63e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EGFR—pancreatic cancer	5.28e-06	6.62e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	5.23e-06	6.56e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APOE—pancreatic cancer	5.23e-06	6.56e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	5.2e-06	6.52e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PPARG—pancreatic cancer	5.2e-06	6.52e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	5.18e-06	6.5e-05	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	5.14e-06	6.45e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TYMS—pancreatic cancer	5.13e-06	6.44e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CD44—pancreatic cancer	5.11e-06	6.41e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	5.09e-06	6.39e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.07e-06	6.36e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—AKT1—pancreatic cancer	5.07e-06	6.36e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	5.02e-06	6.29e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—KRAS—pancreatic cancer	4.99e-06	6.26e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.97e-06	6.23e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.96e-06	6.22e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	4.96e-06	6.22e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APOE—pancreatic cancer	4.93e-06	6.18e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MYC—pancreatic cancer	4.93e-06	6.18e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	4.92e-06	6.17e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	4.91e-06	6.16e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	4.91e-06	6.16e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GCG—pancreatic cancer	4.9e-06	6.15e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AKT1—pancreatic cancer	4.88e-06	6.12e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	4.84e-06	6.07e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	4.82e-06	6.05e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	4.81e-06	6.04e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.81e-06	6.03e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	4.78e-06	6e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CD—pancreatic cancer	4.74e-06	5.94e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CG—pancreatic cancer	4.72e-06	5.92e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PPARG—pancreatic cancer	4.67e-06	5.86e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	4.67e-06	5.85e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	4.62e-06	5.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—STK11—pancreatic cancer	4.61e-06	5.78e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	4.59e-06	5.76e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PIK3CA—pancreatic cancer	4.58e-06	5.75e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PPARG—pancreatic cancer	4.56e-06	5.71e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	4.55e-06	5.71e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTEN—pancreatic cancer	4.52e-06	5.67e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.51e-06	5.66e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.45e-06	5.58e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	4.44e-06	5.57e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—pancreatic cancer	4.43e-06	5.56e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	4.42e-06	5.55e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.37e-06	5.49e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	4.32e-06	5.42e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	4.3e-06	5.4e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.29e-06	5.39e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	4.28e-06	5.37e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	4.27e-06	5.35e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	4.26e-06	5.35e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	4.25e-06	5.33e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—HRAS—pancreatic cancer	4.24e-06	5.32e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	4.2e-06	5.27e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.18e-06	5.25e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	4.18e-06	5.24e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	4.18e-06	5.24e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APOE—pancreatic cancer	4.18e-06	5.24e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	4.15e-06	5.21e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.15e-06	5.21e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CB—pancreatic cancer	4.13e-06	5.18e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS2—pancreatic cancer	4.09e-06	5.13e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.06e-06	5.09e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	4.05e-06	5.08e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.05e-06	5.08e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	4.02e-06	5.05e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	3.98e-06	4.99e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	3.97e-06	4.97e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.96e-06	4.97e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.95e-06	4.96e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	3.92e-06	4.91e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.91e-06	4.91e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	3.89e-06	4.88e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.88e-06	4.86e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	3.87e-06	4.85e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	3.85e-06	4.83e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	3.8e-06	4.77e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	3.78e-06	4.74e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	3.77e-06	4.73e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	3.75e-06	4.71e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AKT1—pancreatic cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	3.72e-06	4.66e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	3.71e-06	4.65e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	3.71e-06	4.65e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	3.69e-06	4.63e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	3.67e-06	4.61e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS2—pancreatic cancer	3.67e-06	4.61e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPARG—pancreatic cancer	3.64e-06	4.56e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.62e-06	4.54e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.58e-06	4.5e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTEN—pancreatic cancer	3.57e-06	4.47e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.51e-06	4.4e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	3.45e-06	4.33e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	3.44e-06	4.32e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.42e-06	4.29e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.41e-06	4.28e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.41e-06	4.28e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	3.38e-06	4.24e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.38e-06	4.24e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	3.38e-06	4.24e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.38e-06	4.23e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	3.37e-06	4.23e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.31e-06	4.16e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	3.27e-06	4.1e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOE—pancreatic cancer	3.22e-06	4.04e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTEN—pancreatic cancer	3.2e-06	4.02e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	3.19e-06	4e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	3.19e-06	4e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	3.14e-06	3.94e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	3.13e-06	3.93e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTEN—pancreatic cancer	3.13e-06	3.92e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.12e-06	3.92e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	3.07e-06	3.85e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.95e-06	3.69e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.93e-06	3.68e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.91e-06	3.65e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.9e-06	3.64e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	2.89e-06	3.62e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS2—pancreatic cancer	2.86e-06	3.59e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	2.84e-06	3.56e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.81e-06	3.52e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.76e-06	3.46e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	2.71e-06	3.4e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.67e-06	3.34e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.61e-06	3.27e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.58e-06	3.24e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.56e-06	3.21e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CA—pancreatic cancer	2.52e-06	3.16e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.5e-06	3.13e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.47e-06	3.09e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	2.39e-06	3e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.26e-06	2.83e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.23e-06	2.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.21e-06	2.77e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.21e-06	2.77e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.18e-06	2.73e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.08e-06	2.61e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AKT1—pancreatic cancer	2.06e-06	2.58e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.93e-06	2.42e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AKT1—pancreatic cancer	1.85e-06	2.31e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AKT1—pancreatic cancer	1.8e-06	2.26e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.76e-06	2.21e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.7e-06	2.13e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.44e-06	1.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.36e-06	1.7e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.11e-06	1.39e-05	CbGpPWpGaD
